Literature DB >> 16479563

Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over.

F M-S Barthel1, A Babiker, P Royston, M K B Parmar.   

Abstract

We present a general framework for sample size calculation in survival studies based on comparing two or more survival distributions using any one of a class of tests including the logrank test. Incorporated within this framework are the possible presence of non-uniform staggered patient entry, non-proportional hazards, loss to follow-up and treatment changes including cross-over between treatment arms. The framework is very general in nature and is based on using piecewise exponential distributions to model the survival distributions. We illustrate the use of the approach and explore its validity using simulation studies. These studies have shown that not adjusting for loss to follow-up, non-proportional hazards or cross-over can lead to significant alterations in power or equivalently, a marked effect on sample size. The approach has been implemented in the freely available program ART (for Stata). Our investigations suggest that ART is the first software to allow incorporation of all these elements. Further extensions to the methodology such as non-local alternatives for the logrank test are also considered. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16479563     DOI: 10.1002/sim.2517

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  21 in total

1.  Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study.

Authors:  Donglin Zeng; Qingxia Chen; Ming-Hui Chen; Joseph G Ibrahim
Journal:  Biometrika       Date:  2011-12-29       Impact factor: 2.445

2.  The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression.

Authors:  Olivia I Okereke; Charles F Reynolds; David Mischoulon; Grace Chang; Nancy R Cook; Trisha Copeland; Georgina Friedenberg; Julie E Buring; JoAnn E Manson
Journal:  Contemp Clin Trials       Date:  2018-03-08       Impact factor: 2.226

3.  A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.

Authors:  Fang Xia; Stephen L George; Xiaofei Wang
Journal:  Stat Biopharm Res       Date:  2016-03-22       Impact factor: 1.452

4.  Functional status after injury: a longitudinal study of geriatric trauma.

Authors:  Lorraine Kelley-Quon; Lillian Min; Eric Morley; Jonathan R Hiatt; Henry Cryer; Areti Tillou
Journal:  Am Surg       Date:  2010-10       Impact factor: 0.688

5.  Sample size calculation for the proportional hazards cure model.

Authors:  Songfeng Wang; Jiajia Zhang; Wenbin Lu
Journal:  Stat Med       Date:  2012-07-11       Impact factor: 2.373

6.  miR-520h is crucial for DAPK2 regulation and breast cancer progression.

Authors:  C-M Su; M-Y Wang; C-C Hong; H-A Chen; Y-H Su; C-H Wu; M-T Huang; Y-W Chang; S-S Jiang; S-Y Sung; J-Y Chang; L-T Chen; P-S Chen; J-L Su
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

7.  Effect of combined folic acid, vitamin B(6), and vitamin B(12) on colorectal adenoma.

Authors:  Yiqing Song; Joann E Manson; I-Min Lee; Nancy R Cook; Ligi Paul; Jacob Selhub; Edward Giovannucci; Shumin M Zhang
Journal:  J Natl Cancer Inst       Date:  2012-10-12       Impact factor: 13.506

8.  Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model.

Authors:  Jianrong Wu
Journal:  Stat Biopharm Res       Date:  2017-03-02       Impact factor: 1.452

9.  Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Stat Biopharm Res       Date:  2017-03-02       Impact factor: 1.452

10.  Early antiretroviral therapy and mortality among HIV-infected infants.

Authors:  Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.